The company believes that its current cash, cash equivalents, and short-term investments, including proceeds from the ATM and January financing, will be sufficient to fund its operations into the second half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRDN:
- Viridian Therapeutics names Jennifer Tousignant chief legal officer
- Insider Trading: Viridian (NASDAQ:VRDN) Sees Huge Insider Buy
- Viridian Therapeutics price target lowered to $39 from $40 at Wedbush
- Viridian Therapeutics 7.14M share Spot Secondary priced at $21.00
- Viridian announces offering of common stock, Series B preferred stock